Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. develops and commercializes nitric oxide-based medical device and biopharmaceutical programs. Its recurring news centers on LungFit PH, a tankless inhaled nitric oxide system that uses Plasma Pulse Technology to generate nitric oxide from room air, and on commercial access through hospital purchasing channels.
Company updates also cover nitric oxide programs for respiratory indications, including severe lung infections, and Beyond Cancer's ultra-high concentration nitric oxide, or UNO, platform for investigational solid-tumor immunotherapy. Additional recurring themes include clinical data presentations, scientific publications, intellectual property, leadership changes, investor conferences, and governance matters.
Beyond Cancer (NASDAQ: XAIR) reported updated Phase 1 UNO data and a U.S. patent allowance on April 20, 2026. Follow-up shows 6 of 10 heavily pretreated patients alive 22–40 months after a single intratumoral UNO injection; median overall survival not reached. Two triple negative breast cancer patients show no evidence of disease. Safety was generally favorable; one treatment-related serious adverse event (hypoxia) resolved. The USPTO issued a Notice of Allowance for a gas-delivery patent that will strengthen the UNO intellectual property portfolio.
Beyond Air (NASDAQ: XAIR) announced that CEO Robert Goodman and CFO Dan Moorhead will participate in the D. Boral Capital Global Conference 2026 on May 7, 2026 at The Plaza Hotel in New York.
The company will hold one-on-one meetings with investors; interested parties should contact their D. Boral Capital representative to request scheduling.
Beyond Air (NASDAQ: XAIR) announced a national group purchasing agreement, effective April 1, 2026, enabling participating member hospitals and health systems to access the LungFit® PH system.
According to the company, the agreement expands commercial reach by nearly 2,000 U.S. hospitals and health systems and builds on existing GPO relationships including Vizient and Premier, increasing adoption pathways for its tankless nitric oxide solution that generates NO on demand from room air.
Beyond Air (NASDAQ: XAIR) announced that CEO Steve Lisi resigned effective March 27, 2026, and the Board appointed Chief Commercial Officer Robert Goodman as CEO effective March 26, 2026. Mr. Lisi led development and launch of LungFit PH during his nine-year tenure.
The Board said the transition aims to accelerate market adoption and scale commercial growth, highlighting Mr. Goodman’s commercial and international experience and the Company’s expectation of no disruption to operations or customer relationships.
Beyond Cancer (NASDAQ: XAIR) reported interim Phase 1 UNO data showing early clinical activity and a favorable safety profile after a single intratumoral injection in ten heavily pretreated patients with cutaneous or subcutaneous tumors.
Key points: two triple negative breast cancer patients show no evidence of disease, seven patients alive 19–37 months post‑treatment, most adverse events Grade 1, one treatment‑related serious hypoxia event that resolved.
Beyond Air (NASDAQ: XAIR) announced that CEO Steve Lisi will participate in the 38th Annual Roth Conference in Laguna Niguel, CA, March 22–24, 2026.
Steve Lisi will appear for a fireside chat and one-on-one meetings on Monday, March 23 at 8:00am PT. A live webcast is available and an archive will be posted for 90 days after the event. Investors seeking a one-on-one should contact their bank representative to request a meeting.
Beyond Air (NASDAQ: XAIR) announced that the previously disclosed proposed sale of its NeuroNOS subsidiary to XTL Biopharmaceuticals Ltd. will not proceed. A January 2026 letter of intent expired on March 9, 2026 and the parties did not execute a definitive agreement.
The company said it will retain its interest in NeuroNOS, continue to evaluate strategic alternatives for the NeuroNOS platform, and remain focused on advancing its core nitric oxide platform and LungFit programs.
Beyond Air (NASDAQ: XAIR) commented on a landmark independent review published Feb 2026 that synthesizes data from 27 studies on high‑dose inhaled nitric oxide (iNO) delivered well above the FDA‑approved 20 ppm. The review highlights multimodal antimicrobial activity, potential in pneumonia, NTM, bronchiolitis, COVID‑19, and a roadmap for future research.
Beyond Air noted the review reinforces momentum behind its clinical programs and could accelerate development of high‑dose iNO as a novel respiratory antimicrobial.
Beyond Air (NASDAQ: XAIR) reported fiscal Q3 2026 results with revenue up 105% YoY to $2.2M, gross profit of $0.3M, and net loss of $7.3M (‑$0.85/sh). Pro forma cash totaled $22.3M, including $4.5M net PIPE proceeds, which the company says funds operations into calendar 2027. The company maintained FY2026 revenue guidance of $8–10M and announced a binding LOI for NeuroNOS consideration up to $32.5M plus 19.99% equity in XTL.
Beyond Cancer (NASDAQ: XAIR) was selected to present Phase 1 data on intratumoral ultra-high concentration nitric oxide (UNO) in solid tumor metastases at the AACR Annual Meeting 2026 in San Diego.
The abstract will be presented April 19, 2026 (Poster Section 13, Poster Board 22, Poster Number 304) and the itinerary text is scheduled for online publication March 17, 2026 at 4:30 PM ET.